Bausch Health(BHC)

QUEBEC, Quebec, Canada

Pharmaceutical

Website LinkedIn Careers Page

Focus: Small Molecules

Bausch Health is a life sciences company focused on Small Molecules.

ImmunologyGastroenterologyNeurologyCardiovascularInfectious Diseases

Funding Stage

PUBLIC

Open Jobs

Products & Portfolio (11)

35 discontinued products not shown

Corticosteroid Hormone Receptor Agonists

CLINICAL PHARMACOLOGY Bumex is a loop diuretic with a rapid onset and short duration of action. Pharmacological and clinical studies have shown that 1 mg Bumex has a diuretic potency equivalent to approximately 40 mg furosemide. The major site of Bumex action is the ascending limb of the loop of Henle. The mode of action has been determined through various clearance studies in both humans and experimental animals. Bumex inhibits sodium reabsorption in the ascending limb of the loop of Henle, as shown by marked reduction of free-water clearance (CH 2 O) during hydration and tubular free-water reabsorption (T H 2 O) during hydropenia. Reabsorption of chloride in the ascending limb is also blocked by Bumex, and Bumex is somewhat more chloruretic than natriuretic. Potassium excretion is also increased by Bumex, in a dose-related fashion. Bumex may have an additional action in the proximal tubule. Since phosphate reabsorption takes place largely in the proximal tubule, phosphaturia during Bumex induced diuresis is indicative of this additional action. This is further supported by the reduction in the renal clearance of Bumex by probenecid, associated with diminution in the natriuretic response. This proximal tubular activity does not seem to be related to an inhibition of carbonic anhydrase. Bumex does not appear to have a noticeable action on the distal tubule. Bumex decreases uric acid excretion and increases serum uric acid. Following oral administration of Bumex the onset of diuresis occurs in 30 to 60 minutes. Peak activity is reached between 1 and 2 hours. At usual doses (1 mg to 2 mg) diuresis is largely complete within 4 hours; with higher doses, the diuretic action lasts for 4 to 6 hours. Diuresis starts within minutes following an intravenous injection and reaches maximum levels within 15 to 30 minutes. Several pharmacokinetic studies have shown that bumetanide, administered orally or parenterally, is eliminated rapidly in humans, with a half-life of between 1 and 1½ hours. Plasma protein-binding is in the range of 94% to 96%. Oral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Urinary and biliary metabolites identified in this study were formed by oxidation of the N-butyl side chain. Biliary excretion of Bumex amounted to only 2% of the administered dose. Pediatric Pharmacology Elimination of bumetanide appears to be considerably slower in neonatal patients compared with adults, possibly because of immature renal and hepatobiliary function in this population. Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg. In a population of neonates receiving bumetanide for volume overload, mean serum clearance ra

edema associated with congestive heart failurehepaticrenal disease+2 more

ORAL · CAPSULE, EXTENDED RELEASE

Cytochrome P450 3A4 Inducers

acute manicgeneralized tonic-clonic seizuresmixed seizures ( ) 1+4 more

1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The relative beta 1 -selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta 2 -mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine. (2) In asthmatic patients, metoprolol reduces FEV 1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta 1 -receptor blocking doses. Hypertension: The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. However, several possible mechanisms have been proposed: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output; (2) a central effect leading to reduced sympathetic outflow to the periphery; and (3) suppression of renin activity. Angina Pectoris: By blocking catecholamine-induced increases in heart rate, in velocity and extent of myocardial contraction, and in blood pressure, metoprolol reduces the oxygen requirements of the heart at any given level of effort, thus making it useful in the long-term management of angina pectoris. Heart Failure: The precise mechanism for the beneficial effects of beta-blockers in heart failure has not been elucidated.

hypertension in adult patientsto lower blood pressurethe long-term treatment of angina pectoris+6 more

1978

LOTENSIN

benazepril hydrochloride

LOE Approaching

ORAL · TABLET

angiotensin-converting enzyme (ACE) in human subjects and animals. Benazeprilat has much greater ACE inhibitory activity than does benazepril. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. In animal studies, benazepril had no inhibitory effect on the vasopressor response to angiotensin II and did not interfere with the hemodynamic effects of the autonomic neurotransmitters acetylcholine, epinephrine, and norepinephrine. ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of Lotensin remains to be elucidated. While the mechanism through which benazepril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, benazepril has an antihypertensive effect even in patients with low-renin hypertension.

hypertensionto lower blood pressure

1991

LOTENSIN HCT

benazepril hydrochloride and hydrochlorothiazide

LOE Approaching

ORAL · TABLET

CLINICAL PHARMACOLOGY Mechanism of Action Benazepril and benazeprilat inhibit angiotensin converting enzyme (ACE) in human subjects and in animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. Hypertensive patients treated with benazepril alone for up to 52 weeks had elevations of serum potassium of up to 0.2 mEq/L. Similar patients treated with benazepril and hydrochlorothiazide for up to 24 weeks had no consistent changes in their serum potassium (see ) . Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. In animal studies, benazepril had no inhibitory effect on the vasopressor response to angiotensin II and did not interfere with the hemodynamic effects of the autonomic neurotransmitters acetylcholine, epinephrine, and norepinephrine. ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of Benazepril HCl and Hydrochlorothiazide remains to be elucidated. While the mechanism through which benazepril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, benazepril has an antihypertensive effect even in patients with low-renin hypertension. Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin aldosterone link is mediated by angiotensin, so coadministration of an ACE inhibitor tends to reverse the potassium loss associated with these diuretics. The mechanism of the antihypertensive effect of thiazides is unknown. Pharmacokinetics and Metabolism Following oral administration of Benazepril HCl and Hydrochlorothiazide, peak plasma concentrations of benazepril are reached within 0.5 to 1.0 hour. As determined by urinary recovery, the extent of absorption is at least 37%. In fasting subjects, the rate and extent of absorption of benazepril and hydrochlorothiazide from Benazepril HCl and Hydrochlorothiazide are not different, respectively, from the rate and extent of absorption of benazepril and hydrochlorothiazide from immediate release monotherapy formulations. The estimated absolute bioavailability of hydrochlorothiazide after oral administration is about 70%.

hypertension

1992

MOVIPREP

polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate

LOE Approaching

ORAL · FOR SOLUTION

3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, which induce a laxative effect. The physiological consequence is increased water retention in the lumen of the colon, resulting in loose stools.

2006

NORPRAMIN

desipramine hydrochloride

LOE Approaching

ORAL · TABLET

Mechanism of Action Available evidence suggests that many depressions have a biochemical basis in the form of a relative deficiency of neurotransmitters such as norepinephrine and serotonin. Norepinephrine deficiency may be associated with relatively low urinary 3-methoxy-4-hydroxyphenyl glycol (MHPG) levels, while serotonin deficiencies may be associated with low spinal fluid levels of 5-hydroxyindoleacetic acid. While the precise mechanism of action of the tricyclic antidepressants is unknown, a leading theory suggests that they restore normal levels of neurotransmitters by blocking the re-uptake of these substances from the synapse in the central nervous system. Evidence indicates that the secondary amine tricyclic antidepressants, including NORPRAMIN, may have greater activity in blocking the re-uptake of norepinephrine. Tertiary amine tricyclic antidepressants, such as amitriptyline, may have greater effect on serotonin re-uptake. NORPRAMIN is not a monoamine oxidase inhibitor (MAOI) and does not act primarily as a central nervous system stimulant. It has been found in some studies to have a more rapid onset of action than imipramine. Earliest therapeutic effects may occasionally be seen in 2 to 5 days, but full treatment benefit usually requires 2 to 3 weeks to obtain.

depression

1964

RELISTOR

methylnaltrexone bromide

Peak

SUBCUTANEOUS · SOLUTION

Pipeline & Clinical Trials

Pergolide

Parkinson Disease

N/A

Clinical Trials (1)

NCT00624741Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

N/A

Trulign™ Toric IOL

Cataract

N/A

Poly-L-Lactic Acid Injection

Healthy Volunteers

N/A

Clinical Trials (1)

NCT00869687Biopsy Study for Sculptra (Poly-L-Lactic Acid)

N/A

Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy

Colonoscopy

N/A

Clinical Trials (1)

NCT00929916Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy

N/A

SRP + MM

Periodontitis

N/A

Clinical Trials (1)

NCT05422742Influence of SRP With MM on the Composition and Functional Characteristics of Subgingival Microbiome Communities

N/A

Rifaximin

Intestinal FDG Uptake

N/A

Clinical Trials (1)

NCT01542541A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

N/A

Rifaximin

Hepatic Encephalopathy

N/A

Clinical Trials (1)

NCT00533910Rifaximin in Minimal Hepatic Encephalopathy

N/A

Efudex

Photo-aging

N/A

Clinical Trials (1)

NCT00121511The Effect of Efudex Treatment on Photoaged Skin

N/A

dihydroergotamine mesylate

Migraine

N/A

Clinical Trials (1)

NCT00203268A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity

N/A

EYEFILL® C.-US Viscoelastic

Cataract

N/A

Brodalumab

Psoriasis

N/A

Clinical Trials (1)

NCT05132231Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

N/A

Effectivity of Dermatix in Promoting Scar Maturation

Hypertrophic Scars

N/A

Clinical Trials (1)

NCT00548210Effectivity of Dermatix in Promoting Scar Maturation

N/A

Once a day Trientine

Wilson Disease

N/A

Clinical Trials (1)

NCT01472874Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease

N/A

Rifaximin

Hepatic Encephalopathy

N/A

Clinical Trials (1)

NCT01846806The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.

N/A

Salix Probiotic Blend

Functional Gastrointestinal Disorders

N/A

Clinical Trials (1)

NCT04155801A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances

N/A

Thermage FLX

Facial Skin Laxity

N/A

Clinical Trials (1)

NCT03894371Thermage FLX System to Treat the Face, Neck, and Eyelids

N/A

Rifaximin

Liver Cirrhosis

N/A

Clinical Trials (1)

NCT01951209Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

N/A

Methylnaltrexone

Opioid-induced Constipation

N/A

Clinical Trials (1)

NCT01368562Compassionate Use Study of Methylnaltrexone

N/A

CLEAR + BRILLIANT TOUCH

Photoaging

N/A

Clinical Trials (1)

NCT05027282Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment

N/A

Neomycin

Constipation-predominant Irritable Bowel Syndrome

N/A

Clinical Trials (1)

NCT00945334Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

N/A

Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incont

Fecal Incontinence

N/A

Clinical Trials (1)

NCT01647906Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)

N/A

CeraVe Baby Diaper Rash Cream

Diaper Rash

N/A

Clinical Trials (1)

NCT02299206CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants

N/A

Fipamezole ODT

Parkinson's Disease

N/A

Clinical Trials (1)

NCT01140841A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa

N/A

Thermage FLX

Wrinkle

N/A

Clinical Trials (1)

NCT07187297A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment

N/A

Thermage FLX

Skin Wrinkling

N/A

Clinical Trials (1)

NCT04606368Bausch Health Thermage FXL for Use on Lower Face and Submentum Area

N/A

Brodalumab

Psoriasis

N/A

Clinical Trials (1)

NCT03254667LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

N/A

3.75% Imiquimod Cream

Mycosis Fungoides

N/A

Clinical Trials (1)

NCT02301494Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

N/A

Brodalumab

Psoriasis

N/A

Clinical Trials (1)

NCT04149587A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

N/A

Pimecrolimus

Atopic Dermatitis

N/A

Clinical Trials (1)

NCT0056899710 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

N/A

DL6049

Mid Facial Contour Deficiencies

N/A

Clinical Trials (1)

NCT00487474A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCULPTRA Measured by Three Dimensional Digital Surface Imaging

N/A

Sculptra

Acne Vulgaris

N/A

Clinical Trials (1)

NCT00795327Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring

N/A

Fipamezole ODT

Parkinson's Disease

N/A

Clinical Trials (1)

NCT01149811A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease

N/A

Bausch + Lomb Samfilcon A Soft Contact Lens

Myopia

N/A

Clinical Trials (1)

NCT02939950Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis

N/A

NASHA/Dx

Fecal Incontinence

N/A

Clinical Trials (1)

NCT00605826A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence

N/A

PEG-SD

Hyponatremia

N/A

Clinical Trials (1)

NCT01299779Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS

N/A

Rifaximin

Celiac Disease

N/A

Clinical Trials (1)

NCT01137955Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

N/A

SCULPTRA

Facial Lipoatrophy

N/A

Clinical Trials (1)

NCT00360932Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

N/A

Plecanatide

Chronic Idiopathic Constipation

N/A

Clinical Trials (1)

NCT03551873A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

N/A

Fraxel® FTX Laser System

Skin Resurfacing

N/A

Clinical Trials (1)

NCT07214272A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

N/A

clindamycin phosphate, adapalene and benzoyl peroxide

Acne Vulgaris

N/A

Clinical Trials (1)

NCT07205107Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

N/A

SC Methylnaltrexone

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT01367496Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Phase 1

MOA-728

Metahdone-maintenance Subjects

Phase 1

Clinical Trials (1)

NCT00398502Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone

Phase 1

MNTX tablet

Normal Volunteers

Phase 1

Clinical Trials (1)

NCT01366352Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

Phase 1

rifaximin

Pharmacokinetic

Phase 1

Clinical Trials (1)

NCT00743912Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers

Phase 1

IDP-118 Lotion

Psoriasis

Phase 1

Clinical Trials (1)

NCT03058744Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

Phase 1

MOA-728

Constipation

Phase 1

Clinical Trials (1)

NCT00444158Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects

Phase 1

MOA-728

Adult

Phase 1

Clinical Trials (1)

NCT00387491Dose Ranging Study in Healthy Methadone Maintenance Subjects

Phase 1

MOA-728

Healthy

Phase 1

Clinical Trials (1)

NCT00434395Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

Phase 1

Methylnaltrexone

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT01363323Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

Phase 1

50 mg/mL Virazole

COVID19

Phase 1

Clinical Trials (1)

NCT04356677Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 46 approved products, 48 clinical trials

Top TAs: Cardiovascular, Gastroenterology, Nephrology

SEC Filings: 2 available

Portfolio Health

Pre-Launch15 (33%)

Peak2 (4%)

LOE Approaching23 (50%)

Post-LOE6 (13%)

46 total products

Therapeutic Area Focus

7 marketed

3 marketed

3 marketed

2 marketed

2 marketed

1 marketed

1 marketed

1 marketed

Marketed

Pipeline

Financials (FY2025)

Revenue

$8.8B8%

R&D Spend

$604M(7%)14%

Net Income

-$592M

Cash

$947M

Source: SEC 10-K Filing